TY - JOUR
T1 - Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes
AU - Bordon, Jose
AU - Aliberti, Stefano
AU - Duvvuri, Padmaraj
AU - Wiemken, Timothy
AU - Peyrani, Paula
AU - Natividad, Inez
AU - Caceres-Lara, Alfredo
AU - Delapenha, Robert
AU - Blasi, Francesco
AU - Ramirez, Julio
PY - 2013/5
Y1 - 2013/5
N2 - Background: The effect of time of the first antimicrobial dose (TFAD) on the outcomes of community-acquired pneumonia (CAP) remains a controversy. Methods: This was an observational, retrospective study of consecutive adult patients hospitalized with CAP. TFAD was defined as the time in hours from arrival at the emergency department to the intravenous infusion of antimicrobial. All patients received appropriate antibiotic therapy according to available Infectious Diseases Society of America/American Thoracic Society guidelines during the time of our study. Multivariable analysis and a propensity score adjusted methodology were used to measure the association of TFAD with mortality, time to clinical stability (TCS), and length of stay in the hospital (LOS). Results: Data of 372 patients with CAP were studied. A total 29 (8.4%) patients died within 30 days of hospitalization. Our propensity-adjusted logistic regression model did not show a significant association between TFAD and mortality (p= 0.148). Patients who died received antimicrobials significantly earlier than survivors: 5.7. h vs. 7.5. h, respectively (p= 0.04). The LOS and TCS were not significantly affected by the TFAD; the LOS hazard ratio was 0.996 (95% confidence interval 0.97-1.02; p= 0.774) and the TCS hazard ratio was 1.01 (95% confidence interval 0.98-1.03; p= 0.604). Conclusions: TFAD does not seem to be associated with the clinical outcome of patients with CAP. Early TFAD should be considered as an important marker of optimal care of patients with CAP rather than as a factor predicting outcomes.
AB - Background: The effect of time of the first antimicrobial dose (TFAD) on the outcomes of community-acquired pneumonia (CAP) remains a controversy. Methods: This was an observational, retrospective study of consecutive adult patients hospitalized with CAP. TFAD was defined as the time in hours from arrival at the emergency department to the intravenous infusion of antimicrobial. All patients received appropriate antibiotic therapy according to available Infectious Diseases Society of America/American Thoracic Society guidelines during the time of our study. Multivariable analysis and a propensity score adjusted methodology were used to measure the association of TFAD with mortality, time to clinical stability (TCS), and length of stay in the hospital (LOS). Results: Data of 372 patients with CAP were studied. A total 29 (8.4%) patients died within 30 days of hospitalization. Our propensity-adjusted logistic regression model did not show a significant association between TFAD and mortality (p= 0.148). Patients who died received antimicrobials significantly earlier than survivors: 5.7. h vs. 7.5. h, respectively (p= 0.04). The LOS and TCS were not significantly affected by the TFAD; the LOS hazard ratio was 0.996 (95% confidence interval 0.97-1.02; p= 0.774) and the TCS hazard ratio was 1.01 (95% confidence interval 0.98-1.03; p= 0.604). Conclusions: TFAD does not seem to be associated with the clinical outcome of patients with CAP. Early TFAD should be considered as an important marker of optimal care of patients with CAP rather than as a factor predicting outcomes.
KW - Community-acquired pneumonia
KW - Mortality
KW - Outcomes
KW - Time to first antibiotic dose
UR - http://www.scopus.com/inward/record.url?scp=84876090518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876090518&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2012.09.021
DO - 10.1016/j.ijid.2012.09.021
M3 - Article
C2 - 23507237
AN - SCOPUS:84876090518
VL - 17
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
IS - 5
ER -